Acceleron to Host Conference Call & Webcast to Review Data Presented at the 59th American Society of Hematology Annual Meetin...
05 Diciembre 2017 - 6:00AM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN) will host a conference call
and live audio webcast on Monday, December 11, 2017 at 7:00 a.m.
EST to review highlights from its Phase 2 clinical presentations at
the 59th American Society of Hematology (ASH) Annual Meeting and
Exposition taking place December 9-12, 2017 in Atlanta,
Georgia.
Participants can access the live conference call by dialing
877-312-5848 (domestic) or
253-237-1155 (international) and referring to the
Acceleron ASH 2017 update.
The live webcast can be accessed on the Investors page of the
company's website at www.acceleronpharma.com.
A replay of the webcast will be available approximately two
hours after the event on the Acceleron website.
About Acceleron
Acceleron is a Cambridge-based, clinical-stage
biopharmaceutical company dedicated to the discovery, development,
and commercialization of therapeutics to treat serious and rare
diseases. The Company's leadership in the understanding of TGF-beta
biology and protein engineering generates innovative compounds that
engage the body's ability to regulate cellular growth and
repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Celgene, are
developing luspatercept for the treatment of chronic anemia in
myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
Acceleron is also advancing its neuromuscular franchise with two
distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary
program with a Phase 2 trial of sotatercept planned in pulmonary
arterial hypertension.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma
and LinkedIn.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171205005546/en/
Acceleron Pharma Inc.Todd James, IRC, 617-649-9393Vice
President, Investor Relations and Corporate CommunicationsorCandice
Ellis, 617-649-9226Manager, Investor Relations and Corporate
CommunicationsorMedia:BMC CommunicationsBrad Miles,
646-513-3125
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024
